MPV Diagnostic Reagents Differentiating Avian Pneumovirus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for respiratory diseases in mammals, particularly humans, face challenges due to the genetic similarity between mammalian metapneumoviruses (MPV) and avian pneumoviruses (APV), making specific diagnosis and treatment difficult, and there is a need for effective methods to identify and manage MPV infections.
Innovation Solution
The development of specific reagents and diagnostic kits that utilize nucleic acid and protein sequences unique to MPV, allowing for accurate identification and differentiation from APV, along with the use of cross-reactive reagents for diagnosis and potential vaccine development using chimeric virus constructs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then diagnosis can be performed, but diagnostic accuracy deteriorates due to genetic similarity between MPV and APV
Solution Approach 1:
The patent segments the diagnostic approach by developing species-specific primers and probes that target unique genomic regions of MPV, separating the detection of MPV from APV despite their overall genetic similarity. This allows specific identification of MPV sequences distinct from APV sequences.
Solution Approach 2:
The patent applies local quality by identifying and targeting specific local regions within the MPV genome that differ from APV, using species-specific oligonucleotides that bind only to MPV-specific sequences rather than attempting to detect entire viral genomes.
2Reliability
If broad-spectrum antiviral treatments are used, then treatment can be provided, but treatment effectiveness deteriorates due to inability to specifically target MPV
Solution Approach 1:
The patent segments the therapeutic approach by developing MPV-specific antiviral agents that target only MPV infection, separating MPV treatment from general respiratory virus treatment. This enables reliable treatment specifically adapted to MPV pathogenesis.
Solution Approach 2:
The patent applies parameter changes by developing treatments with specific pharmacokinetic and pharmacodynamic parameters optimized for MPV, including species-specific dosing regimens and delivery methods tailored to MPV infection characteristics in mammals.
3Measurement precision
If phylogenetic analysis is used, then virus identification can be performed, but identification time increases due to complex analytical procedures
Solution Approach 1:
The patent applies preliminary action by pre-designing and storing MPV-specific primers and probes based on known MPV sequence characteristics, so that when a clinical sample is received, identification can proceed immediately without needing to perform full phylogenetic sequencing and analysis.
Solution Approach 2:
The patent extracts only the essential diagnostic information by using targeted PCR and hybridization assays that detect specific MPV sequences, extracting only the necessary identification data rather than performing complete genomic sequencing and phylogenetic analysis.
Data Source
AI summary
The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single stranded RNA virus (MPV) within the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.